<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>
  • Using technology in tumor genomics to develop precision cancer therapeutics

    Investor Relations

Press Releases

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2017 Archives

May 25, 2017
Study evaluated safety, dose limiting toxicities, related maximum tolerated dose and indication of anti-tumor activity in patients with advanced or metastatic solid tumors
Apr 13, 2017
Revised model factoring in PCM-075 (AML drug) as the key driver of the company going forward - sets $4 target price.
Apr 12, 2017
Maxim Group upgrades Trovagene from a "hold" position to a "buy" position based on PCM-075 (AML drug candidate) as the key driver of the company going forward
Mar 15, 2017
Announces restructuring program to support its expansion into precision cancer therapeutics
Mar 7, 2017
Authors conclude that ctDNA testing demonstrates clinical utility in assessing disease burden and response to therapy
Jan 24, 2017
Performance of Trovera™ ctDNA KRAS in blood and urine has similar concordance to standard of care tissue molecular diagnostics
Jan 12, 2017
Seven new partners to commercialize Trovera™ liquid biopsy tests in Europe and the Middle East

email print rss
Wistia video thumbnail - Susann-Berz Patient Video- Home Page

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?